# AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

> **NCT01281254** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 223 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** AMG386 plus PLD
- **DRUG:** Placebo plus PLD

## Key facts

- **NCT ID:** NCT01281254
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04-18
- **Primary completion:** 2014-08-29
- **Final completion:** 2017-04-19
- **Target enrollment:** 223 (ACTUAL)
- **Why stopped:** Closure of long term follow up (LTFU) and study earlier than previously outlined in the protocol as no beneficial information gained from continuing LTFU.
- **Last updated:** 2017-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281254, "AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT01281254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*